Drugs / PTW-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05529134 | Apr 2023 → Apr 2024 | epidermolysis bullosa dystrophica | Phoenicis Therapeutics | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTW-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05529134 ↗ |
| Route | Topical | “poloxamer hydrogel for topical administration” NCT05529134 ↗ |